Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: High efficacy and no serious adverse events

Acta Dermato-Venereologica

Volumn 93, Issue 3, 2013, Pages 346-349

  Seidling, Vera ^a   Hoffmann, Jochen H O ^a   Enk, Alexander H ^a   Eva, N Hadaschik ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Autoimmune mucocutaneous blistering disease; Bullous pemphigoid; High dose intravenous immunoglobulin therapy; Pemphigus foliaceus; Pemphigus vulgaris

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTRATECT; UNCLASSIFIED DRUG;

ADULT; ANAPHYLAXIS; ARTICLE; BACKACHE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLURRED VISION; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PETECHIA; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; SCORING SYSTEM; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; VERTIGO;

ADULT; AGED; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; PEMPHIGOID, BULLOUS; PEMPHIGUS; RETROSPECTIVE STUDIES; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875464229     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1471     Document Type: Article

References (15)

1. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002; 46: 42-49.
2. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139: 1051-1059.
3. Onal S, Foster CS, Ahmed AR. Efficacy of intravenous im-munoglobulin treatment in refractory uveitis. Ocul Immunol Infamm 2006; 14: 367-374.
4. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999; 119: 231-238.
5. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004; 111: 1380-1382.
6. Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009; 19: 90-98.
7. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999; 8: 705-712.
8. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64: 903-908.
9. Gurcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007; 41: 812-823.
10. Engineer L, Bhol kc, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1049-1057.
11. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous im-munoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.
12. Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Br J Dermatol 2009; 160: 1098-1102.
13. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on defnitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
14. Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007; 41: 1604-1610.
15. Ahmed AR, Spigelman Z, cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.